Stock Taper
SCREENER COMPARE ANY 2 STOCKS
DYN
DYNE THERAPEUTICS, INC.
NASDAQ
$25.07
▼ DOWN 3.91% (-1.02)

KEY STATISTICS

Market Cap$4.68 B
52w High$27.30
52w Low$11.92
Dividend Yield—
Frequency—
P/E-7.79
Volume1.19M
Shares Out.186.75M

COMPANY

LEADERSHIP

John G. Cox
CHIEF EXECUTIVE
John G. Cox

COMPENSATION 2026

Salary$721,000
Stock Awards$0
Incentive Plan Pay$410,970
All Other Comp.$7,005
Total$2,076,868

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 17, 2020
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
289

PRICE TARGET

Target High$50.00
Target Low$24.00
Target Median$38.00
Target Consensus$38.00

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.—
NOV
4
WED

PRICE

$25.07 ▼ DOWN 3.91% (−$1.02)
$24.80$25.20$25.60$26.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM25.07

About Dyne Therapeutics, Inc.

https://www.dyne-tx.com ↗

Dyne Therapeutics, Inc., founded in 2017 and based in Waltham, MA, develops disease-modifying therapies for genetically driven muscle diseases like DMD, myotonic dystrophy, and FSHD using its FORCE platform.

INDUSTRY

Biotechnology

A PRODUCT DYNE THERAPEUTICS, INC. IS KNOWN FOR

DYNE-251 (zeleciment rostudirsen)
DYNE-251 (zeleciment rostudirsen)

An investigational antisense oligonucleotide for Duchenne muscular dystrophy targeting exon 51 skipping, showing promising clinical results and aiming for U.S. accelerated approval in Q2 2026, making it Dyne's leading drug candidate.

COMPETITORS

COMPETITOR
CAPR COMPARE
EWTX COMPARE
PTCT COMPARE
RNA COMPARE
SRPT COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
149
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.01% · 5.3M
XBI
0.97% · 4.4M
IWM
0.12% · 3.9M
SCHA
0.09% · 783.0K
DFAS
0.08% · 477.4K
TCAF
0.15% · 476.2K
SBIO
2.12% · 203.9K
LABU
0.66% · 160.5K
XRSU.L
0.12% · 137.6K
FESM
0.05% · 123.3K
PRFZ
0.08% · 82.9K
RSSL
0.12% · 72.3K
BBSC
0.17% · 49.8K
OP
OPTZ
0.26% · 30.9K
BBC
0.86% · 17.2K
WBIO.L
1.03% · 13.1K
TILT
0.01% · 12.2K
HLTH
2.97% · 9.1K
SGRW
0.73% · 8.3K
URTY
0.05% · 6.2K
STXK
0.16% · 5.4K
BKSE
0.13% · 4.8K
RFLR
0.13% · 4.8K
ESSC
0.23% · 3.3K
VETS
0.16% · 2.8K
PQ
PQSG
0.22% · 1.5K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
67.92%
HOLDERS
340
TOP 12 OF 340 · RANKED BY POSITION SIZE
T. Rowe Price Investment Management, Inc.
30.9M sh · $686.56M
Janus Henderson Group Plc
14.7M sh · $186.49M
Blackrock, Inc.
12.4M sh · $275.5M
Vanguard Group Inc
11.2M sh · $219.38M
Fmr LLC
11.2M sh · $248.91M
Atlas Venture Life Science Advisors, LLC
9.1M sh · $165.54M
State Street Corp
7.5M sh · $165.65M
Blackrock Inc.
7.4M sh · $260.69M
Orbis Allan Gray Ltd
7.0M sh · $155.62M
Fcpm Iii Services B.V.
5.5M sh · $106.85M
Adage Capital Partners Gp, L.L.C.
5.2M sh · $101.16M
Siren, L.L.C.
4.7M sh · $59.82M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
Rhodes Jason P
Sale · 478.4K shares
2026-08-14
★
DIRECTOR
Rhodes Jason P
Sale · 63.6K shares
2026-08-13
★
DIRECTOR
Rhodes Jason P
Sale · 322.5K shares
2026-08-14
★
OFFICER: CHIEF FINANCIAL OFFICER
Lucera Erick
Sale · 1.8K shares
2026-08-13

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 3
BUY 3
OVERWEIGHT 1
MARKET PERFORM 1
NEUTRAL 1
9 GRADES IN THE LAST 12 MONTHS
Morgan Stanley OVERWEIGHT RBC Capital OUTPERFORM Evercore ISI Group OUTPERFORM Bernstein MARKET PERFORM Chardan Capital BUY HC Wainwright & Co. BUY JP Morgan NEUTRAL Stifel BUY

SECTORS PEERS

PEERPRICE
APGE$134.97COMPARE
CGON$74.34COMPARE
MIRM$97.46COMPARE
XENE$59.99COMPARE
CELC$88.44COMPARE
TLX$11.29COMPARE
RARE$25.61COMPARE
AAPG$18.28COMPARE